Thus, Liu and coworkers showed that lung cancer cells surviving to cisplatin treatment are enriched in CD133+ cells, displaying multiple drug resistance mainly related to expression of the drug transporter ABCG2 [160]. This evidence concerns the gene PROM1 and lung carcinoma.